Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Francesca Bruce

Senior Writer

Francesca writes about a broad range of policy and regulatory topics, including intellectual property rights. However, her main areas of expertise are pricing and reimbursement and how medicines may or may not make it to patients. She writes about developments in Europe and is also expanding coverage in emerging markets, including Latin America and the Middle East. Francesca writes for Pink Sheet, Scrip and In Vivo.

Latest From Francesca Bruce

European Commission Dangles Conditional Approval Reprieve For PTC Therapeutics’ Translarna

Scientific questions from member state experts and a recent court ruling on impartiality in the drug approval process prompted the European Commission to query the EMA’s negative opinion on PTC’s Translarna.

Europe Drug Review

Colombia Signs Agreement With PAHO To Strengthen Regulatory Capacity

The deal comes at a time when Latin American countries are increasingly looking to improve the regulatory environment for pharmaceuticals and move towards greater convergence.

South America Colombia

Industry Calls For More Clarity On EU Compulsory Licensing Proposal

Industry groups say the initiative will undermine innovation and the competitiveness of European companies, impeding Europe's ability to tackle future crises effectively.

Europe Innovation

Brazil Pursues Regulatory Reliance Strategy For GMP Inspections

Brazil has listed 42 international regulatory bodies as equivalent authorities, including US FDA and the EU’s EMA.

South America Brazil

Are Managed Entry Agreements The Answer To EU Market Access For ATMPs?

EU-level action on market access could include a “solidarity fund” for ultra-rare disease treatments and a new framework for managed entry agreements.

Europe Gene Therapy

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

The European Parliament has voted for a deal agreed with the council of minister to ensure polluters pay for cleaning up urban wastewater.

Europe Germany
See All
UsernamePublicRestriction

Register